Stopping nucleos(t)ide analogues (NA) in chronic hepatitis B (CHB) patients can increase HBsAg loss rates. However, long-term follow-up (FU) data after NA cessation among a multiethnic population are lacking. This study aimed to assess the long-term outcomes after NA cessation in a large global cohort.
Journal of Hepatology published a clinical update in Research Highlights on 29 Mar 2026.
The item focuses on Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B – follow-up from the RETRACT-B cohort.
Review the original article for the full source wording and details.